Therapeutic treatment methods
View Patent ↗The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.
1. A composition comprising one or more excipients and a compound having the structure
wherein the dotted lines are optional double bonds;
R 1 is —OH or an ester;
R 2 is —H, —OH or an ester;
R 3 is —H, —OH, a halogen or an ester;
R 4 in the β-configuration is —OH, an ester or an amino acid and R 4 in the α-configuration is —H or optionally substituted alkynyl;
R 5 is —CH 3 or —C 2 H 5 ;
R 10A is —OH or R 10A is —H or —OH when R 2 is —OH or an ester; and
R 10B is a halogen.
2. The composition of claim 1 wherein R 3 is —OH, a halogen or an ester and the compound has the structure
3. The composition of claim 2 wherein R 5 is —CH 3 .
4. The composition of claim 3 wherein R 10B is —F.
5. The composition of claim 4 having the structure
6. The composition of claim 2 wherein R 4 in the α-configuration is alkynyl.
7. The composition of claim 2 wherein the composition is a pharmaceutical formulation.
8. The composition of claim 1 wherein the compound has the structure
9. The composition of claim 8 wherein the compound has the structure
10. The composition of claim 9 wherein R 10B is —F.
11. The composition of claim 10 wherein R 5 is —CH 3 .
12. The composition of claim 11 having the structure
13. The composition of claim 12 having the structure
14. The composition of claim 12 wherein R 4 in the α-configuration is alkynyl.
15. The composition of claim 12 wherein R 4 in the α-configuration is —H.
16. The composition of claim 15 wherein R 4 in the β-configuration is —OH.
17. The composition of claim 16 wherein R 2 is —H or —OH.
18. The composition of claim 17 wherein the compound is 1 α,3β17β-trihydroxy-4α-fluoroandrost-5-ene.
19. The composition of claim 8 wherein the composition is a pharmaceutical formulation.